Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis


  • Filippo Rumi Alta Scuola di Economia e Management dei Sistemi Sanitari, Università Cattolica del Sacro Cuore, Roma - Italy
  • Michele Basile Alta Scuola di Economia e Management dei Sistemi Sanitari, Università Cattolica del Sacro Cuore, Roma - Italy
  • Americo Cicchetti Alta Scuola di Economia e Management dei Sistemi Sanitari, Università Cattolica del Sacro Cuore, Roma - Italy
  • Rosario Contiguglia Dirigente Medico Specialista in Pneumologia Responsabile Home Care Respiratoria presso Asp Messina - Italy
  • Antonella Pentassuglia Dirigente Medico Specialista presso il Servizio di Broncopneumologia, Ospedale San Giovanni Battista – Cavalieri di Malta, Roma - Italy
  • Alessandro Oliva Dirigente Medico presso Pneumologia ASO Mauriziano di Torino - Italy
  • Gianenrico Senna Primario presso il reparto di Allergologia Ospedale Policlinico G.B. Rossi di Borgo Roma, Verona - Italy
  • Marco Bonavia Responsabile Struttura Semplice Pneumologia Riabilitativa Asl3 Genovese Ospedale La Colletta, Arenzano (GE) - Italy
  • Francesco Scarpelli Medico presso UO Riabilitazione Area Ospedaliera Don Uva, Bisceglie (BT) - Italy
  • Marco Benvenuto Ricercatore Universitario, Economia Aziendale, Dipartimento di Scienze dell’Economia, Università del Salento, Lecce - Italy



Adherence, Asthma, Budget impact analysis, Economic evaluation, Telemedicine


Introduction: Adherence to long-term asthma control drugs is one of the key factors in improving disease management among patients with asthma. Poor adherence to long-term therapies significantly compromises the effectiveness of treatment and represents a problem in controlling the disease in terms of quality of life and economic impact. A budget impact analysis has been developed taking into account that Turbo+ technology (electronic monitoring device) can increase adherence to therapy in patients suffering from asthma.

Methods: Coherently with the budget impact model methodology, we developed two different scenarios. One represents the clinical practice assuming a constant market share of 0,99% for Turbo+ and the other one assumes an incremental market share of Turbo+ over the time horizon considered. An increase in adherence to therapy will likely correspond to a reduction of exacerbations and a lower rate of hospitalizations, thus generating savings in terms of use of health resources.

Results: The differential analysis shows an incremental saving in terms of resources absorbed by the National Health Service (NHS) over the time horizon considered. In the first year the savings are equal to € 795,658.64 and in the fifth year they are equal to € 3,520,636.34 for a total of resources saved in 5 years of € 10,882,028.50.

Conclusions. The model shows how the diffusion of the Turbo+ programme can lead to savings in terms of health resources consumed by the NHS. Further analyses with new real-world data on adherence in asthmatic patients could be useful in confirming the results of the present analysis.


Download data is not yet available.


Global Asthma Network. The Global Asthma Report 2018. Online: ; (Accessed June 2021)

Vos T, Lim SS, Abbafati C, et al; GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. PMID:33069326 DOI:

Brian C. Leutholtz, Ignacio Ripoll, Exercise and disease management, 2nd. CRC Press; 2011:100. DOI:

Global Initiative for Asthma (GINA) - Global Strategy for Asthma Management and Prevention; Online:; (Accessed May 2021)

Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics. 2006;24(7):695-708. PMID: 16802845. DOI:

Vogelmeier C, D’Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J. 2005;26(5):819-828. PMID:16264042 DOI:

Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2019 global survey. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO; Online: (Accessed May 2021)

Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004;114(6):1288-1293. PMID:15577825 DOI:

Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45(2):396-407. PMID:25323234 DOI:

L’uso dei farmaci in Italia – Rapporto nazionale anno 2019; Online:; (Accessed May 2021)

Agenzia Italiana del Farmaco (AIFA); Online: (Accessed May 2021)

Istituto Nazionale di Statistica – Popolazione residente al 1° gennaio – Online:; (Accessed May 2021)

Jensen, F.F., Håkansson, K.E.J., Overgaard Nielsen, B. et al. Self-reported vs. objectively assessed adherence to inhaled corticosteroids in asthma. Asthma Res Pract. 2021 May 31;7(1):7. PMID: 34059120 DOI:

Pesce G, Locatelli F, Cerveri I, et al. Seventy Years of Asthma in Italy: Age, Period and Cohort Effects on Incidence and Remission of Self-Reported Asthma from 1940 to 2010. PLoS One. 2015;10(10):e0138570. PMID:26439263 DOI:

Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J. 2004;23(5):723-729. PMID:15176687 DOI:

Ministero della Salute - Tariffario delle prestazioni di assistenza specialistica per acuti (DRG); Online: (Accessed May 2021)

Prestazioni Di Assistenza Specialistica Ambulatoriale – Allegato III – Online:; (Accessed May 2021)

Ministero della Salute – Telemedicina – Linee di indirizzo Nazionali. Online: (Accessed May 2021)



How to Cite

Rumi, F., Basile, M., Cicchetti, A., Contiguglia, R., Pentassuglia, A., Oliva, A., Senna, G., Bonavia, M., Scarpelli, F., & Benvenuto, M. (2022). Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis. Global and Regional Health Technology Assessment, 9(1), 58–67.



Original Research Articles


Received 2021-07-05
Accepted 2022-03-14
Published 2022-04-19


Most read articles by the same author(s)

1 2 > >>